We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00976950
First Posted: September 15, 2009
Last Update Posted: March 20, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Boehringer Ingelheim
  Purpose
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease inhibitor.

Condition Intervention
HIV Infections Drug: Tipranavir Drug: ritonavir

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Tipranavir (Aptivus®) Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Number of Patients Reporting Adverse Events (AE) [ Time Frame: 48 weeks ]
    Any type of adverse events


Secondary Outcome Measures:
  • Virologic Response [ Time Frame: 48 weeks ]
    Virologic response is defined as HIV viral load of < 50 copies/mL before week 48 and without subsequent rebound or change of ARV therapy prior to week 48. A rebound is defined by two consecutive measurements of VL >= 50 copies/ml, at least two weeks apart, after two consecutive measurements of VL< 50 copies/ml. Because of many missing data concerning the viral load, the virologic response could be determined only for four patients.

  • Change in CD4+ Cell Count From Baseline at Week 48 [ Time Frame: 48 weeks ]

Enrollment: 42
Study Start Date: September 2009
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with HIV-1 infection Drug: Tipranavir Drug: ritonavir
low-dose

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients
Criteria

Inclusion criteria:

  1. HIV-1 infected patients who are treatment experienced and infected with HIV-1 strains resistant to more than one protease inhibitor and no other therapeutic options.
  2. The inclusion criteria follow the same criteria which are describe in the newest SPC

Exclusion criteria:

The exclusion criteria follow the same criteria which are describe in the newest SPC

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00976950


Locations
Romania
Boehringer Ingelheim Investigational site 9
Arad, Romania
Boehringer Ingelheim Investigational site 13
Bacau, Romania
Boehringer Ingelheim Investigational site 17
Brasov, Romania
Boehringer Ingelheim Investigational site 18
Brasov, Romania
Boehringer Ingelheim Investigational site 19
Brasov, Romania
Boehringer Ingelheim Investigational site 1
Bucuresti, Romania
Boehringer Ingelheim Investigational site 2
Bucuresti, Romania
Boehringer Ingelheim Investigational site 3
Bucuresti, Romania
Boehringer Ingelheim Investigational site 4
Bucuresti, Romania
Boehringer Ingelheim Investigational site 5
Bucuresti, Romania
Boehringer Ingelheim Investigational site 6
Bucuresti, Romania
Boehringer Ingelheim Investigational site 7
Bucuresti, Romania
Boehringer Ingelheim Investigational site 8
Bucuresti, Romania
Boehringer Ingelheim Investigational site 16
Constanta, Romania
Boehringer Ingelheim Investigational site 11
Craiova, Romania
Boehringer Ingelheim Investigational site 12
Craiova, Romania
Boehringer Ingelheim Investigational site 15
Galati, Romania
Boehringer Ingelheim Investigational site 20
Tg.Mures, Romania
Boehringer Ingelheim Investigational site 10
Timisoara, Romania
Boehringer Ingelheim Investigational site 14
Vaslui, Romania
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00976950     History of Changes
Other Study ID Numbers: 1182.147
First Submitted: September 14, 2009
First Posted: September 15, 2009
Results First Submitted: May 30, 2012
Results First Posted: August 16, 2012
Last Update Posted: March 20, 2014
Last Verified: February 2014

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Ritonavir
Tipranavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors